

## Literatuuroverzicht tot 23-04-2020

1. **Pentoxifylline and severe acute respiratory syndrome (SARS): A drug to be considered.** Bermejo Martín JF, Jiménez JL, Muñoz-Fernández MA. *Medical Science Monitor*. 2003;9(6):SR29-SR34.
2. **Community acquired pulmonary infection: Clinical perspectives.** Carter R, Woodhead M. *CPD Journal Radiology Update*. 2007;6(2):97-106.
3. **The role of disposable inhalers in pulmonary drug delivery.** De Boer AH, Hagedoorn P. *Expert Opinion on Drug Delivery*. 2015;12(1):143-57.
4. **Bronchial anthracofibrosis in an east indian immigrant living in Northwest Ohio.** Flora A, Alim H, Stein A, Andandan V, Willey J. *American Journal of Respiratory and Critical Care Medicine*. 2017;195.
5. **Effectiveness of anti-allergic drugs used to treat anaphylactic reactions associated with sting challenge tests: A retrospective data-base analysis.** Garaganova J, Linhardt A, Bielicky L, Ruëff F. *Allergy: European Journal of Allergy and Clinical Immunology*. 2013;68:634.
6. **Advances in antivirals for non-influenza respiratory virus infections.** Hayden FG. *Influenza and other Respiratory Viruses*. 2013;7:36-43.
7. **Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors.** Hui DS, Joynt GM, Wong KT, Gomersall CD, Li TS, Antonio G, et al. *Thorax*. 2005;60(5):401-9. <http://dx.doi.org/10.1136/thx.2004.030205>.
8. **Adjunctive therapies and immunomodulating agents for severe influenza.** Hui DSC, Lee N. *Influenza and other Respiratory Viruses*. 2013;7:52-9.
9. **Overview of the 3rd isirv-Antiviral Group Conference - advances in clinical management.** Hurt AC, Hui DS, Hay A, Hayden FG. *Influenza and other Respiratory Viruses*. 2015;9(1):20-31.
10. **Combination of Sarsasapogenin and Fluticasone attenuates ovalbumin-induced airway inflammation in a mouse asthma model.** Ingawale DK, Mandlik SK, Patel SS. *Immunopharmacology and Immunotoxicology*. 2020;42(2):128-37.
11. **New respiratory viruses and the elderly.** Jartti L, Langen H, Söderlund-Venermo M, Vuorinen T, Ruuskanen O, Jartti T. *Open Respiratory Medicine Journal*. 2011;5(1):61-9.
12. **Clinical characteristics of 42 SARS patients and their treatment of integrative Chinese and western medicine.** Jin-pan Z, Bao-jin H, Chang-huai C, Gui-cheng X, Hao S, Yin W, et al. *Chinese Journal of Integrative Medicine*. 2003;9(3):169-74.
13. **Metered-dose inhaler with spacer instead of nebulizer during the outbreak of severe acute respiratory syndrome in Singapore.** Khoo SM, Tan LK, Said N, Lim TK. *Respiratory Care*. 2009;54(7):855-60.
14. **Current challenges in lower respiratory infections in children.** Klig JE. *Current Opinion in Pediatrics*. 2004;16(1):107-12.
15. **Respiratory Virus Detection in Nasal Lavage Fluid of Chronic Rhinosinusitis Patients During Acute Exacerbations.** Kwah J, Benjamin MR, Fischer S, Biyasheva A, Hadzic A, Kato A, et al. *Journal of Allergy and Clinical Immunology*. 2019;143(2):AB86.
16. **Is respiratory viral infection really an important trigger of asthma exacerbations in children?** Lee SL, Chiu SSS, Malik PJS, Chan KH, Wong HSW, Lau YL. *European Journal of Pediatrics*. 2011;170(10):1317-24.

17. **Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan.** Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. *The Journal of allergy and clinical immunology*. 2020. <http://dx.doi.org/10.1016/j.jaci.2020.04.006>.
18. **Analysis of Epidemiological and Clinical features in older patients with Corona Virus Disease 2019 (COVID-19) out of Wuhan.** Lian J, Jin X, Hao S, Cai H, Zhang S, Zheng L, et al. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2020.
19. **Major advances in respiratory medicine in China.** Liu HJ, Shi HZ. *Chinese Medical Journal*. 2009;122(17):2054-60.
20. **Preliminary analysis of treatment in 32 patients with critical severe acute respiratory syndrome.** Lu W, Zhang H, Wang F, Wang S, Wu X, Zhang N, et al. *Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue*. 2003;15(8):492-4.
21. **Three men, a paint brush and a coronavirus.** MacConnachie AA, Collins TC, Seaton RA, Kennedy DH. *International Journal of STD and AIDS*. 2007;18(2):132-3.
22. **Invasive aspergillosis in a patient with asthma post H1N1 Pneumonia** Nayar<sup>1</sup>, Cook P<sup>1</sup>, Lim L<sup>1</sup>, Allison D<sup>1</sup>, Denning D<sup>2</sup>county Durham and Darlington foundation trust<sup>1</sup>national aspergillosis centre, university hospital of South Manchester<sup>2</sup>category: Clinical lesson. Nayar D, Cook P, Lim L, Allison D, Denning DW. *Journal of Infection*. 2011;63(6):e103-e4.
23. **Effect of pretreatment with omalizumab with or without antihistamines on the tolerability of immunotherapy in patients with asthma inadequately controlled with inhaled corticosteroids.** Panahloo Z, Casale T, Massanari M, Nelson H, Busse W, Kianifard F, et al. *Allergy: European Journal of Allergy and Clinical Immunology*. 2009;64:344.
24. **A case report of idiopathic acute fibrinous pneumonia and a review of the literature.** Rafii R, Murin S, Morrissey BM. *Chest*. 2010;138(4).
25. **Synthesis and biological evaluation of Ginsenoside Compound K analogues as a novel class of anti-asthmatic agents.** Ren S, Liu R, Wang Y, Ding N, Li Y. *Bioorganic and Medicinal Chemistry Letters*. 2019;29(1):51-5.
26. **Pulmonary diseases and corticosteroids.** Sethi GR, Singhal KK. *Indian Journal of Pediatrics*. 2008;75(10):1045-56.
27. **Time-course of upper respiratory tract viral infection and COPD exacerbation.** Stolz D, Papakonstantinou E, Grize L, Schilter D, Strobel W, Louis R, et al. *European Respiratory Journal*. 2019;54(4).
28. **Microbial biotransformation of bioactive and clinically useful steroids and some salient features of steroids and biotransformation.** Sultana N. *Steroids*. 2018;136:76-92.
29. **Dynamic changes in clinical features and cytokine/chemokine responses in SARS patients treated with interferon alfacon-1 plus corticosteroids.** Ward SE, Loutfy MR, Blatt LM, Siminovitch KA, Chen J, Hinek A, et al. *Antiviral Therapy*. 2005;10(2):263-75.
30. **Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells.** Yamaya M, Nishimura H, Deng X, Sugawara M, Watanabe O, Nomura K, et al. *Respiratory investigation*. 2020.